Gilead Sciences has said it will soon start clinical trials for inhaled formulation of its antiviral drug remdesivir used for the treatment of Covid-19. The US drugmaker said the trials will begin in August.
Posted from: this blog via Microsoft Flow.
No comments:
Post a Comment